Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany.
effectiveness
metastatic
real-world evidence
sacituzumab govitecan
safety
triple-negative breast cancer
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
02
2023
accepted:
25
08
2023
medline:
4
10
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
Sacituzumab govitecan has been recently approved by the USFDA and EMA for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). We report real-world safety and effectiveness in patients with mTNBC receiving sacituzumab govitecan treatment at a breast cancer centre in Germany. Data from patients who had received sacituzumab govitecan as treatment for mTNBC, in both Patients ( The real-world safety and effectiveness profile of sacituzumab govitecan in patients with mTNBC are in line with clinical trial data. Further studies are required to guide optimal use of sacituzumab govitecan against mTNBC, especially in context of management of accompanying AEs.
Sections du résumé
Background
UNASSIGNED
Sacituzumab govitecan has been recently approved by the USFDA and EMA for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). We report real-world safety and effectiveness in patients with mTNBC receiving sacituzumab govitecan treatment at a breast cancer centre in Germany.
Methods
UNASSIGNED
Data from patients who had received sacituzumab govitecan as treatment for mTNBC, in both
Results
UNASSIGNED
Patients (
Conclusion
UNASSIGNED
The real-world safety and effectiveness profile of sacituzumab govitecan in patients with mTNBC are in line with clinical trial data. Further studies are required to guide optimal use of sacituzumab govitecan against mTNBC, especially in context of management of accompanying AEs.
Identifiants
pubmed: 37789989
doi: 10.1177/17588359231200454
pii: 10.1177_17588359231200454
pmc: PMC10542232
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359231200454Informations de copyright
© The Author(s), 2023.
Références
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Chem Rev. 2009 Jul;109(7):2894-902
pubmed: 19476377
Ann Oncol. 2021 Feb;32(2):240-249
pubmed: 33242536
N Engl J Med. 2022 Jul 21;387(3):217-226
pubmed: 35857659
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
J Clin Oncol. 2021 May 1;39(13):1485-1505
pubmed: 33507815
Ann Oncol. 2020 Dec;31(12):1709-1718
pubmed: 32946924
NPJ Breast Cancer. 2022 Jun 9;8(1):72
pubmed: 35680967
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1101-1111
pubmed: 34629489
NPJ Breast Cancer. 2022 Aug 29;8(1):98
pubmed: 36038616
Ann Oncol. 2021 Sep;32(9):1148-1156
pubmed: 34116144
Breast Cancer Res Treat. 2022 Sep;195(2):127-139
pubmed: 35545724
Clin Breast Cancer. 2009 Feb;9(1):29-33
pubmed: 19299237
Ther Adv Med Oncol. 2020 May 11;12:1758835920915980
pubmed: 32426047
Eur J Cancer. 2023 Jan;178:23-33
pubmed: 36379186
J Clin Oncol. 2022 Oct 10;40(29):3365-3376
pubmed: 36027558
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
Breast Cancer Res Treat. 2017 Feb;161(3):549-556
pubmed: 28000014
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
Ann Oncol. 2021 Jun;32(6):746-756
pubmed: 33741442
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
J Clin Oncol. 2017 Jul 1;35(19):2141-2148
pubmed: 28291390